KO Client Kailera Therapeutics Announces Positive Topline Data from Two Clinical Trials

KO client Kailera Therapeutics, a clinical-stage biotechnology company focused on elevating the next era of obesity care, recently announced positive topline data from two Phase 3 clinical trials for people living with obesity or type 2 diabetes.

KO partner Brad Schoenfeld and attorney John Shearer represented Kailera in getting the clinical trial up and running. Read more in the announcement.